Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 7/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139994 | 0.85 | HSD17B10 (0.48) | ALDH1A1KDM4EPOLBTSHRKMT2A | |
| SCHEMBL6848933 | 0.84 | TNF (0.40) | TNFKAT2BALDH1A1KDM4ELMNA | |
| SCHEMBL21248414 | 0.74 | CYP1A2 (0.45) | ALDH1A1KDM4E | |
| SCHEMBL11210438 | 0.73 | TNF (0.52) | TNFKAT2BALDH1A1LMNAGAA | |
| SCHEMBL7141645 | 0.70 | HSD17B10 (0.43) | ALDH1A1KDM4EPOLBTSHRMEN1 | |
| SCHEMBL15081130 | 0.68 | LMNA (0.47) | TNFKAT2BALDH1A1KDM4ELMNA | |
| SCHEMBL6848920 | 0.67 | TNF (0.50) | TNFKAT2BALDH1A1KDM4ELMNA | |
| SCHEMBL7430918 | 0.66 | TNF (0.51) | TNFKAT2BLMNANPC1POLB | |
| SCHEMBL29451993 | 0.66 | ALDH1A1 (0.53) | KAT2BALDH1A1LMNANPC1POLB | |
| SCHEMBL6848928 | 0.66 | TNF (0.49) | TNFKAT2BALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777431-B2 | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2004-08-17 | — | — | US | disclosed |
| US-6777431-B2 | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2004-08-17 | — | — | US | disclosed |
| US-6777431-B2 | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | DENDREON PHARMACEUTICALS LLC | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | F2, SERPINC1, F2RL3 | TNF 4841/4885KAT2B 3749/4885ALDH1A1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.